|
Summary of Significant Accounting Policies (Details Narrative) (USD $)
|
12 Months Ended | ||
|---|---|---|---|
|
Dec. 31, 2014
|
Dec. 31, 2013
|
Dec. 31, 2012
|
|
| Cash and Cash Equivalents | $ 2,138,964us-gaap_Cash | $ 888,704us-gaap_Cash | $ 376,421us-gaap_Cash |
| Warrants for services at fair market value | 300,016VNRX_IssuanceOfStockAndWarrantsForServices1 | ||
| Options under the 2011 Equity Incentive Plan at fair market value | 1,385,155VNRX_OptionsUnderEquityIncentivePlanFairValue | ||
| Common stock for services at fair market value | 0VNRX_CommonStockForServicesAtFairMarketValue | ||
| Fair market value of warrants in derivative liability | 1,577,640VNRX_FairMarketValueOfWarrantsInDerivativeLiability | ||
| Accumulated other comprehensive loss | (103,832)us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax | (59,795)us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax | |
| Revenue Recognition | 14,785us-gaap_DeferredRevenueRevenueRecognized | 0us-gaap_DeferredRevenueRevenueRecognized | |
| Research and development expenses | 4,044,023us-gaap_ResearchAndDevelopmentExpense | 2,503,765us-gaap_ResearchAndDevelopmentExpense | |
| Impairment of long-lived assets | $ 0us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf | $ 350,000us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf | |
| Dilutive Warrants And Options [Member] | |||
| Potentially dilutive warrants and options |
966,716VNRX_PotentiallyDilutiveWarrantsAndOptions / us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis = VNRX_DilutiveWarrantsAndOptionsMember |
||
| Warrant [Member] | |||
| Potentially dilutive warrants |
891,045VNRX_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount1 / us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis = us-gaap_WarrantMember |
||
| X | ||||||||||
|
- Definition
Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Amount of previously reported deferred or unearned revenue that was recognized as revenue during the period. Deferred revenue is a liability related to a revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The aggregate amount of write-downs for impairments recognized during the period for long-lived assets held for abandonment, exchange or sale. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Weighted Average Shares Outstanding - Basic and Diluted No definition available.
|
| X | ||||||||||
|
- Definition
Common stock for services at fair market value. No definition available.
|
| X | ||||||||||
|
- Definition
No authoritative reference available. No definition available.
|
| X | ||||||||||
|
- Definition
Warrants for services at fair market value. No definition available.
|
| X | ||||||||||
|
- Definition
Options under the 2011 Equity Incentive Plan at fair market value. No definition available.
|
| X | ||||||||||
|
- Definition
Potentially dilutive warrants and options. No definition available.
|
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Details
|